Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.Kevin Kalinsky, Seth A. Wander, Kyong Hwa Park et al.|Journal of Clinical Oncology|2024Cited by 75
Combination mTORC1/2 and BCL- X<sub>L</sub> inhibition in endocrine and CDK4/6-resistant estrogen receptor-positive breast cancer.Sarah Sammons, Kris C. Wood, Grace R. Anderson et al.|Journal of Clinical Oncology|2019Cited by 2